

## Foreword

On a late spring evening in June 2003, a group of 40 or so scientists stood about on the terrace at Hotel Oud-London, Zeist, The Netherlands. The gathering marked the start of the Third EJP Spring Meeting (13–16 June 2003). Pharmacologists, physiologists, molecular biologists and geneticists representative of research on dopamine, behavioural pharmacology and neurogenetics, would spend the weekend exchanging views, arguing and presenting their work. “Drug targets for psychiatric disorders”, this Special Issue of the European Journal of Pharmacology, presents exciting reviews contributed by the group. This Special Issue reflects the enthusiasm, even excitement that prevailed during the weekend. It will leave the reader with a view of

genotype and phenotype that is truly ground-breaking for neuropharmacology.

J. Peter H. Burbach\*

Roger A.H. Adan

*Department of Pharmacology and Anatomy,*

*Rudolf Magnus Institute of Neuroscience,*

*University Medical Center, Universiteitsweg 100,*

*3584 CG Utrecht, The Netherlands*

*E-mail address:* [j.p.h.burbach@med.uu.nl](mailto:j.p.h.burbach@med.uu.nl)

---

\* Corresponding author. Tel.: +31-30-253-8848/10; fax: +31-30-253-9032.